CD79A and hyper-IgM syndrome type 2: In humans, mutations of huAID are responsible for the Hyper-IgM syndrome type 2 (HIGM2), which is characterized by lack of or very low levels of serum IgG and IgA, absence of IgV somatic mutations, lymphadenopathy and tonsillar hypertrophy, in contrast to healthy donors (41).